According to the Kenya Medical Association, there's a fake Postinor-2, popularly known as P2 that is currently being sold in the East African market.

The fake emergency contraceptive tablets are very similar to the original drug that contains a specific amount of an intrauterine device which prevents pregnancy and treats heavy menstrual bleeding.

Read more about the deatils of the fake P2 below;

Ref. RHT/SAV/Alert 5.2015 18 November 2015

Medical Product Alert N° 5/2015

Falsified Emergency Contraceptive circulating in East Africa

This Medical Product Alert relates to the confirmed circulation of falsified versions of Postinor-2 (Levonorgestrel) in East Africa.

Postinor-2 is a widely used emergency contraceptive that should contain 0.75mg of levonorgestrel. The genuine product is manufactured by Gedeon Richter. In August 2015, the Uganda National Drug Authority notified WHO of the seizure of falsified

Postinor-2 discovered in Kampala, Uganda. All packs reported bear the same batch number and expiry/manufacturing dates.

The details of the product are as follows:

Product Name: Postinor-2

Batch Number: T38012

Manufacturing Date: 08 2013

Expiry Date: 08 2018

There is a non-useable white “scratch area” on the reverse side of the pack,(see photograph above). The packaging is in English, French and Spanish languages. The batch number and manufacturing/expiry dates relate to a genuine batch of Postinor-2. Laboratory analysis has shown that the product contains zero active pharmaceutical ingredient. Furthermore, the manufacturers of genuine Postinor-2 have confirmed the packaging is falsified.

If you are in possession of the same batch of Postinor-2 shown in the below photograph and with a non-useable white “scratch area” on the reverse side of the pack please do not use, contact a Pharmacist or a Doctor as soon as possible for advice and report the incident to your National Medicines Regulatory Authority.

If you think you have taken this product, please seek medical advice immediately.

If you have any information concerning the supply of this product please contact rapidalert@who.int